A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog

Molecular Endocrinology

Volumn 9, Issue 8, 1995, Pages 1053-1063

  Catherino, William H ^a   Wolf, Douglas M ^b   Jordan, V Craig ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; LUCIFERASE; RNA; TAMOXIFEN DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN ACTIVITY; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; TRANSACTIVATION;

AMINO ACID SEQUENCE; CELL DIVISION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS, SYNTHETIC; GROWTH INHIBITORS; HUMAN; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 0029154750     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/mend.9.8.7476979     Document Type: Article

References (70)

1. Tormey DC, Jordan VC 1984 Long-term tamoxifen adjuvant therapy in node positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297-302
2. Delozier R, Julien JP, Juret P, Veyret C, Couette JE, Graic Y, Olllvler JM 1986 Adjuvant tamoxifen treatment of postmenopausal breast cancer: Preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105-110
3. Breast Cancer Trials Committee Scottish Cancer Trials Office (MRC) 1987 Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2: 171-175
4. Early Breast Cancer Trialists Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1-15,71-85
5. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G 1990 Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen vs. four cycles of CMFPT in postmenopausal women with breast cancer: An eastern cooperative oncology group phase III study. J Clin Oncol 8: 599-607
6. Tormey DC, Gray R, Abeloff MD, Roseman DL, Gillchrist KW, Barylak EJ, Stott P, Falkson G 1992 Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An eastern oncology cooperative group trial. J Clin Oncol 10: 1848-1856
7. Robinson SP, Mauel DA, Jordan VC 1989 Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24: 1817-1821
8. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven J 1989 A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126-131
9. Fisher B 1992 The evolution of paradigms for management of breast cancer: A personal perspective. Cancer Res 52: 2371-2383
10. Jordan VC 1993 A current view of tamoxifen for treatment and prevention of breast cancer. Br J Pharmacol 110: 507-517
11. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS 1991 Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst USA 83: 1450-1459
12. Catherino WH, Jordan VC 1993 A risk-benefit assessment of tamoxifen therapy. Drug Saf 8: 381-397
13. Satyaswaroop PG, Zaino RJ, Mortel R 1984 Estrogenlike effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44: 4006-4010
14. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815
15. Legault-Poisson S, Jolivet J, Poisson R, Beretta-Piccoli M, Band PR 1979 Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 63: 1839-1841
16. Canney PA, Griffiths T, Latief TN, Priestman TJ 1987 Clinical significance of tamoxifen withdrawal response. Lancet 1: 36
17. Belani CP, Pearl P, Whitley NO, Aisner J 1989 Tamoxifen withdrawal response. Report of a case. Arch Intern Med 149: 449-450
18. Howell A, Dodwell DJ, Anderson H, Redford J 1992 Response after withdrawal of tamoxifen and progesto-gens in advanced breast cancer. Ann Oncol 3: 611-617
19. Gottardis MM, Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187
20. Gottardis MM, Jiang SY, Jeng MH, Jordan VC 1989 Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093
21. Osborne CK, Coronado EB, Robinson JP 1987 Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189-1196
22. Wlebe VJ, Osborne CK, McGuire WL, DeGregorio MW 1992 Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990-994
23. Wolf DM, Jordan VC 1994 The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31: 129-138
24. Jiang SY, Jordan VC 1992 Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591
25. Jiang SY, Langan-Fahey SM, Stella AL, McCague R, Jordan VC 1992 Point mutation of estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNA’s for ER. Mol Endocrinol 6: 2167-2174
26. Levenson AS, Jordan VC 1994 Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 51: 229-239
27. Jordan VC, Collins MM, Rowsby L, Prestwich G 1977 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305-316
28. Murphy CM, Langan-Fahey SM, McCague R, Jordan VC 1990 Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T 47D breast cancer cells in vitro. Mol Pharmacol 38: 737-743
29. Klein-Hitpaβ L, Schorpp M, Wagner U, Ryffel GU 1986 An estrogen responsive element derived from the 5' flanking region of the Xenopus vitellogenin A 2 gene functions in transfected human cells. Cell 46: 1053-1061
30. Green S, Chambon P 1991 The oestrogen receptor: From perception to mechanism. In: Parker MG (ed) Nuclear Receptors: Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. Academic Press, London, pp 15-37
31. Green S, Issemann I, Sheer E 1988 A versatile in vivo and in vitro eukaryotic vector for protein engineering. Nucleic Acids Res 16: 369
32. Greene GL, Fitch FW, Jensen EV 1980 Monoclonal antibodies to estrophilin: Probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77: 157-161
33. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antioestrogen with clinical potential. Cancer Res 512: 3867-3873
34. Catherino WH, Jordan VC 1995 Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39-47
35. Catherino WH, Wolf DM, Jordan VC, A mutant estrogen receptor derived from a tamoxifen-stimulated human breast cancer cell line. American Association for Cancer Research, 1994, San Francisco, CA (Abstract 1528)
36. Jiang SY, Parker CJ, Jordan VC 1993 A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens. Breast Cancer Res Treat 26: 139-147
37. Horwltz KB 1994 How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol 49: 295-302
38. Wright AP, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, Carlstedt-Duke J, Fustafsson JA 1993 Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 47: 11-19
39. Hughes MR, Malloy PJ, O’Malley BW, Pike JW, Feldman D 1991 Genetic defects of the 1,25-dihydroxyvitamin D 3 receptor. J Recept Res 11: 699-716
40. Pemrick SM, Lucas DA, Grippo JF 1994 The retinoid receptors. Leukemia 8: 1797-1806
41. Chatterjee VK, Beck-Peccoz P 1994 Hormone-nuclear receptor interactions in health and disease. Thyroid hormone resistance. Baillieres Clin Endocinol Metab 8: 267-283
42. Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C, Lobaccaro JM 1993 Mutations of androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem Mol Biol 46: 519-530
43. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, Gronemeyer H 1992 Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 6: 2071-2078
44. Wilding G, Chen M, Gelmann EP 1989 Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115
45. Trapman J, Ris Stalpers C, van der Korput J, Kuiper GG, Faber PW, Romijn JC, Mulder E, Brinkmann A O 1990 The androgen receptor: Functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Mol Biol 37: 837-842
46. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S 1994 Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864
47. Ptashne M, Gann AAF 1990 Activators and targets. Nature 346: 329-331
48. Zajchowski DA, Webster L, Dissection of the mechanism of estrogen and tamoxifen-dependent anti-proliferative effects on ER-transfected human mammary epithelial cells. American Association for Cancer Research, 1994, San Francisco, CA (Abstract 1583)
49. Jordan VC, Jiang SY, Jeng MH, Catherino WH, Wolf DM 1994 Regulation of cell growth with the transfected estrogen receptor gene. In: Motta M, Serio M (eds) Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects. Exerpta Medica, International Congress Series. Elsevier, Amsterdam, pp 243-248
50. Jeng MH, Jiang SY, Jordan VC 1994 Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett 82: 123-128
51. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS 1988 Expression of transforming growth factor a and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543-555
52. Dauvois S, Danielian PS, White R, Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sei USA 89: 4037-4041
53. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG 1990 Inhibition of estrogen receptor-DNA binding by “pure” antiestrogen IC 1164,384 appears to be mediated by Impaired receptor dimerization. Proc Natl Acad Sei USA 87: 6883-6887
54. Brunner N, Frandsen TL, Holst HC, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R 1993 MCF 7/LCC 2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232
55. Hu XF, Veroni M, DeLuise LM, Wakeling A, Sutherland R, Watts CK, Zalcberg JR 1993 Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 55: 873-876
56. Osborne CK 1993 Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47: 83-89
57. Wakeling AE 1993 The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25: 1-9
58. Coopman P, Garcia M, Brunner N, Derocq D, Clarke R, Rochefort H 1994 Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamox-ifen-resistant human breast-cancer cells. Int J Cancer 56: 295-300
59. Lykkesfeldt AE, Madsen MW, Briand P 1994 Altered expression of estrogen-regulated genes in a tamoxifen-resistant and IC 1164,384 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595
60. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE 1994 The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34: 89-95
61. DeFriend D, Howell A, Nicholson R, Anderson E, Dowsett M, Mansel R, Blarney R, Bundred N, Robertson J, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE 1994 Investigation of a new pure antiestrogen (IC 1182, 780) in women with primary breast cancer. Cancer Res 54: 408-414
62. Gronemeyer H, Benhamou B, Berry M, Bocquel MT, Gofflo D, Garcia T, Lerouge T, Metzger D, Meyer ME, Tora L, Vergezac A, Chambon P 1992 Mechanisms of antihormone action. J Steroid Biochem Mol Biol 41: 217-221
63. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477-487
64. Orita M, Suzuki Y, Sekiya T, Hayashi K 1989 Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879
65. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T 1989 Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770
66. Iwahana H, Yoshimoto K, Itakura M 1992 Detection of point mutations by SSCP of PCR-amplified DNA after endonuclease digestion. BioTechniques 12: 64-65
67. Maniatis T, Fritsch EF, Sambrook J 1989 Molecular Cloning-A Laboratory Manual, ed 2. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
68. Law M-F, Byrne JC, Howley PM 1983 A stable bovine papillomavirus hybrid plasmid that expresses a dominant selective trait. Mol Cell Biol 3: 2110-2115
69. LaBarca C, Paigen K 1980 A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102: 344-352
70. MacGregor G, Caskey CT 1989 Construction of plasmids that express E. coli beta-galactosldase in mammalian cells. Nucleic Acids Res 17: 2365